Orrick Advises SFJ Pharmaceuticals on Acquisition of Bentracimab Assets from PhaseBio

1 minute read | January.18.2023

Orrick recently advised SFJ Pharmaceuticals (“SFJ”) on its acquisition of assets related to Bentracimab, a drug with the potential to address a significant unmet need for patients in major bleeding and urgent surgery situations, from PhaseBio Pharmaceuticals, Inc. (“PhaseBio”).

The acquisition was integral to a settlement package previously approved by the United States Bankruptcy Court for the District of Delaware, where PhaseBio’s chapter 11 case has been pending since October 2022.

SFJ is a global drug development company backed by Blackstone Life Sciences and Abingworth and offers a unique and highly customized co-development partnering model for the world’s top pharmaceutical and biotechnology companies.

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases.

The Orrick corporate team was led by Mike O’Donnell, David Gold, and Joanna Pak; the restructuring team was led by Ron D'Aversa, Nick Sabatino, Monica Perrigino, and Vincent Yiu; the bankruptcy litigation team was led by Rich Jacobsen, David Litterine-Kaufman, Ryan Wooten, Nick Poli, James Burke, Ashley Gambone, Michael Buchanan, Rob Wasserstein, Sarah Ungeheuer, Jae Kim, and Mystic Rosa; and the E.D. Pa. litigation team was led by Ben Au, Cathy Lui, Meghan Kelly, Rochelle Swartz, Lauren Kessler, Javier Silva, Camille Rosca, and Zach Kuster.